Trevi Therapeutics, Inc.
NASDAQ:TRVIBiotechnology
+$0.43 today
- Market cap
- $1.93B
- Beta
- 1.05
- P/E (TTM)
- -53.6
- EPS (TTM)
- -$0.31
Volume 2.02M
Average 1.44M
TRVI EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Trevi Therapeutics, Inc.NASDAQ: TRVI
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA remains negative
Q3 FY2026 EBITDA was -$21.43M, compared with -$11.78M a year earlier. Trailing-twelve-month EBITDA was -$60.69M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 10 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the +10.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$21.43M-20.5% QoQ
- Last fiscal yearDec 2025
- -$42.68M+10.7% YoY
- LTMSep 2026
- -$60.69M-32.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -81.9% | +100.0% | +181.9 pp |
| 1 year | +10.7% | +100.0% | +89.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (42.68M) USD
- Year-over-year change
- +10.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (42.68M) | +10.7% |
| FY2024 | 2024-12-31 | (47.79M) | -67.2% |
| FY2023 | 2023-12-31 | (28.58M) | -2.1% |
| FY2022 | 2022-12-31 | (27.98M) | +14.5% |
| FY2021 | 2021-12-31 | (32.71M) | — |
EBITDA vs competitors
How TRVI compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -32.7% is the 7th highest of 9, against a peer median of -9.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $177.83M USD | +245.9% | — | 39.4% | |
| LTM Mar 2026 | $142.5M USD | +440.4% | — | 129.8% | |
| LTM Sep 2026 | $140.29M USD | +5.0% | — | 11.7% | |
| LTM Mar 2026 | -$17.44M USD | +88.7% | — | 25.0% | |
| LTM Mar 2026 | -$57.91M USD | -139.3% | — | — | |
| LTM Sep 2026 | -$60.69M USD | -32.7% | — | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$118.15M USD | -28.2% | — | 590.7% |
UPBUpstream Bio, Inc. | LTM Mar 2026 | -$156.57M USD | -98.0% | — | 4713.1% |
VCREVicore Pharma Holding AB | LTM Jun 2026 | -SEK 248.71M SEK | -24.2% | — | 18700.4% |
| Peer median (excluding TRVI) | — | -9.6% | — | 129.8% | |
Competitors are the stored peer set for TRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 22.98M | 19.83M | 23.68M | 39.38M | 33.48M |
| Selling, General & Admin | 9.49M | 10.07M | 10.24M | 12.15M | 15.85M |
| Operating Expenses | 32.48M | 29.91M | 33.92M | 51.52M | 49.33M |
| Depreciation & Amortization | 50K | 43K | 123K | 147K | 144K |
| EBITDA | (32.71M) | (27.98M) | (28.58M) | (47.79M) | (42.68M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (32.48M) | (29.91M) | (33.92M) | (51.52M) | (49.33M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 10K | 1.74M | 4.75M | 3.6M | 6.54M |
| Interest Expense | 1.2M | 780K | 391K | 4K | 0 |
| Other Income / Expenses | (1.49M) | 719K | 4.83M | 3.58M | 6.51M |
| Income Before Tax | (33.96M) | (29.19M) | (29.1M) | (47.94M) | (42.82M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (21K) | (36K) | (32K) | (30K) | (64K) |
| Net Income | (33.94M) | (29.15M) | (29.07M) | (47.91M) | (42.76M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.49) | (0.45) | (0.29) | (0.47) | (0.29) |
| EPS (Diluted) | (1.49) | (0.45) | (0.29) | (0.47) | (0.29) |
| Weighted Avg Shares | 22.84M | 64.54M | 99.03M | 101.04M | 145.1M |
| Weighted Avg Shares (Diluted) | 22.84M | 64.54M | 99.03M | 101.04M | 145.1M |
Trevi Therapeutics, Inc.
NASDAQ:TRVI
Intrinsic Alpha fair value
Locked
Current Price
$13.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.